Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. - Wikidata - awgldk - TriplyDB

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.

http://www.wikidata.org/entity/Q35650866

about

The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance Effects of Peptide on NK cell-mediated MHC I recognition Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Copy number variation of genes involved in the hepatitis C virus-human interactome HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data Characterization of miR-122-independent propagation of HCV.Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase Antiviral drug resistance as an adaptive process Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate.Read length versus depth of coverage for viral quasispecies reconstruction Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor The three faces of riboviral spontaneous mutation: spectrum, mode of genome replication, and mutation rate.Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase.Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.Application of deep sequence technology in hepatology.Inference with viral quasispecies diversity indices: clonal and NGS approaches.NK cells: tuned by peptide?NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.A small-molecule inhibitor of hepatitis C virus infectivity.

P2860

Q21089768-2A81FFA7-DF79-44E6-85F2-1D201FD465E9 Q26740219-94F831B6-2B81-4195-8FCA-CF04C84BE288 Q26783056-893A391F-0192-4768-AA52-31B869FB83D7 Q26822893-6413FE0B-C987-420E-9A23-EABCCA8CEB25 Q26828727-D0C48839-ABCA-4B9B-A68C-422D4EEA8561 Q27468888-ACBE6DB7-8FEE-4428-9282-3A5E358C8EA2 Q28481038-860119D9-11D2-453F-B76A-F30F20B366EE Q28482493-00A4A11F-6D9E-4BF7-B456-F0E8DBCFFC6C Q28541048-B5C56FA5-75C9-43FC-92C5-292369EA2F21 Q28542443-623361FF-96D7-494D-AB6C-29C2B489940C Q28545971-4EC98728-01AA-4B37-88C4-FE2208D8B7BE Q28553430-6518E858-7702-4B45-A821-1663063D2D6B Q28727944-DD06B5F5-A28E-49F5-A683-04B389270AB2 Q33719172-DD8B73A0-5D8C-498D-92A6-072C79D6890C Q33798503-18CC32DD-223A-441D-8707-E9C1F35DC766 Q33878407-1F612012-B1DD-4B35-BF51-EB4511363993 Q34332546-5A0A14C0-BEC6-4FAE-9EBF-DC213CFD8BC4 Q34395271-B60B7DF3-CE94-488F-9A2B-C16B2ED16E91 Q34442752-2A5597C4-E972-42F4-A7FF-FE24B0507ACE Q34580799-4B1924E6-05AB-455E-82EE-53A1090ABBE8 Q34766299-5BE35DA3-D36D-42FA-89BF-D6025AEC53DE Q36104288-14940B82-FB23-4F04-BB3E-92674A0E5DA1 Q36119900-2C2B0633-3190-41B2-8E0D-BD8232FCA722 Q36505336-8221D8FA-62CE-4AA2-8F3B-88B7D047A32D Q36583173-6D727BCF-DC2B-44A5-9490-436B4FA9577C Q36842286-7D322752-F352-4A6E-A953-784C1C97D3C8 Q36977388-54468B68-C9E7-4843-9D58-FC075CD9E1F9 Q36997093-9B36560E-8AB5-4FB7-8228-8DF9DE0F5DC6 Q37263558-84404DCF-30FD-41F7-B428-0342C87015D6 Q37615174-B1775FA4-73EA-4BE4-AFA9-F47869D87B2F Q37714008-CEC1AA79-E316-4B2D-8162-CB0090E8EC41 Q38125732-775D715B-09F2-4D12-8B50-68FAF0500C72 Q38175788-7CE222B3-C754-468B-B37E-99F293798819 Q38568884-D2B5E6D3-23CA-4F3B-90E7-6991CC8438CD Q38699377-017DFE68-83B7-4132-B505-BD166A92DE30 Q38826176-19007D5B-DBFB-49DF-BF06-E648B4475799 Q38833628-5F96A129-FDD8-435A-9111-1D96FB451AFD Q38849307-B0C6D532-2C1E-4233-83D0-B97E3DB99A20 Q39020651-CF98ED15-6397-49DB-970A-14F3973700F6 Q39069509-8C5CA4D4-B309-417F-A026-3157CC8B21F9

P2860

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.

http://www.wikidata.org/entity/Q35650866

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Contribution of a mutational b ...... evelopment of drug resistance.

@ast

Contribution of a mutational b ...... evelopment of drug resistance.

@en

type

label

Contribution of a mutational b ...... evelopment of drug resistance.

@ast

Contribution of a mutational b ...... evelopment of drug resistance.

@en

prefLabel

Contribution of a mutational b ...... evelopment of drug resistance.

@ast

Contribution of a mutational b ...... evelopment of drug resistance.

@en

P1433

Q35650866-E50358EB-DD28-4024-9E9F-9E7AE93AFFD9

P1476

Q35650866-092E023A-A6FB-49C1-898E-7D1D6BD3D26E

P2093

Q35650866-1EF60CBE-0678-498E-9BF8-77D66844CA36

Q35650866-37BE84FD-47A4-4D19-A60E-F7F46E797493

Q35650866-64167A06-48BE-4B2E-8647-E12527071A26

Q35650866-6576BD19-FD8B-4801-A254-A65AF382C477

Q35650866-A2B65D9F-858D-4285-9160-17ACCBD6A1A3

Q35650866-B493B0AD-141E-4673-8DBA-E7D04127619D

Q35650866-BEDE009C-B9E3-4DD0-8BB6-DE3FACE66A87

Q35650866-CFC92258-BC8D-4933-90D1-183243EAAE14

P2860

Q35650866-0461A8A5-84E7-4301-8FB3-37008BDE78C2

Q35650866-07A08C46-B364-4B8B-9294-88452FEB0646

Q35650866-0A4B6B3F-82F5-474E-8887-F06BDD4F31B5

Q35650866-15DA6458-9063-4C57-BDAB-BA67E13B9F4D

Q35650866-2A3F14F5-B229-4D7D-9E5B-751FEB23C323

Q35650866-2A883958-083B-40D0-8742-42FA57691182

Q35650866-2FC5DDAC-37DC-407D-B4A9-B6B874A8616D

Q35650866-39E3ACD6-188C-42C3-B41F-4E9BEED41DA4

Q35650866-3A2F2276-2B0B-4850-9131-621E1B861AC2

Q35650866-44BA2D45-9211-4F29-87BB-5BF78FD88221

P304

Q35650866-5EFD98FA-87F2-45EC-B550-870637815948

P31

Q35650866-1622643E-A968-4E97-983B-89E8E3FD02E8

P356

Q35650866-DDB3F100-9E77-4593-B136-E32B2A14150C

P407

Q35650866-B33658CF-2173-4D3D-86EF-AC1469334199

P433

Q35650866-9EF28A25-F9F7-4537-A0E6-3550FB119B71

P478

Q35650866-EA24E6A1-F77A-45F3-BC20-454C10C5298D

P50

Q35650866-C4FDEEDA-F149-49AA-82BD-5FFEA028A508

P577

Q35650866-39825A0D-1AB2-4171-BD12-63F40DBAD6EE

P5875

Q35650866-FF7EC4B2-5E23-4CA4-81A2-1DA4F8B02B78

P698

Q35650866-84A53715-58BC-4A29-A903-52898A9E75AA

P921

Q35650866-4D63C8DE-19F9-4B96-9B76-7ABBA646BAFA

P932

Q35650866-236A27AF-A310-450D-BBA6-EE7003B460FD

P356

PNAS.1105797108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Contribution of a mutational b ...... evelopment of drug resistance.

@en

P2093

Egor P Tchesnokov

http://www.w3.org/2001/XMLSchema#string

Evguenia S Svarovskaia

http://www.w3.org/2001/XMLSchema#string

Hongmei Mo

http://www.w3.org/2001/XMLSchema#string

Matthias Götte

http://www.w3.org/2001/XMLSchema#string

Megan H Powdrill

http://www.w3.org/2001/XMLSchema#string

Robert A Kozak

http://www.w3.org/2001/XMLSchema#string

Rodney S Russell

http://www.w3.org/2001/XMLSchema#string

Ross Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Rates of spontaneous mutation among RNA viruses

Boceprevir for previously treated chronic HCV genotype 1 infection

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Rates of evolutionary change in viruses: patterns and determinants

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

P304

20509-20513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1105797108

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51847721

http://www.w3.org/2001/XMLSchema#string

P698

22135458

http://www.w3.org/2001/XMLSchema#string

P921

P932

3251051

http://www.w3.org/2001/XMLSchema#string